We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 12, 2019

Virtual Health Assistants : Clinical and Consumer Perceptions

Commentary
Sophie Madden
&
In 2018, there were around 26.73 million active users of Fitbit products. We know that engagement and interest from consumers in fitness and wellness devices is continuing to grow, but beyond this, it is important to understand how people are engaging with the changing healthcare ecosystem, and what their willingness is to adopt new digital health solutions.


While there is certainly an ample supply of digital health solutions on the market, the demand for these, particularly from consumers, remains widely unknown. HealthXL wanted to gain an understanding on the general consumer perception of these solutions, so we conducted a survey online in February 2019 as part of our Q1 Report on Virtual Health Assistants (VHAs).


VHAs are relational agents or interfaces that are infused with the knowledge of a specific domain that supplement the need for humans in wellness, healthcare, disease management. VHAs enable sharing data, and boost health system capabilities without having to add more bodies. VHAs aim to streamline the healthcare experience for everybody - patients, payers and caregivers. VHAs may take any form factor - they may be voice-based through a home assistant or chat-based via your phone or desktop. AI is generally the underlying technology enabling the conversational element of virtual health assistants.


In this weeks blog, we examine the results of our survey to gain an insight into consumer adoption, awareness, and trust in VHAs, and to explore how our findings may correlate with consumer perceptions of the broader digital health space.


In order for digital health solutions to become an integral part of healthcare delivery, there needs to be awareness of the solutions from all key stakeholders, and to scale, the solution needs to be adopted and trusted by the end-user (patient/healthcare provider) to ensure continued use.


Consumer Survey- What We Found

Some of the key findings from our consumer survey included:


Consumer Awareness

To investigate how aware the general population is of VHAs, we asked survey respondents to identify what online tools, if any, they had used for health guidance and information.

Source: HealthXL Consumer Survey




An interesting divide appeared in the survey results, highlighting the willingness of the sample to use the internet for guidance but a shortfall when it came to those who had actually leveraged a VHA, or digital health solution per se, to date. This highlights a notable opportunity to tap into the willingness of populations to access health support and also the need to champion validated and well connected sources of information to guide them.


When analysing these results, it is important to consider the demographics of the respondents, and how representative they are of the general population. We had respondents from a varied geographic distribution, with the majority based in the US, followed by the EU.  Due to the nature of our survey being carried out online, it is unsurprising that the majority of respondents (48%) are digital natives, aged between 25-34 years old.


Source: HealthXL Consumer Survey


It is important to note that the majority of our survey responses, therefore, reflect the views of millennials. With millenials making up nearly a quarter of the total U.S. population, their needs are highly relevant. Their expectations are changing, driven by increased service and experience expectations in healthcare and comparisons with other industries.


A similar result was observed in a recent report by Oliver Wyman, which explored how awareness and engagement with the changing healthcare model differs among generations. They found that in general, younger generations were more willing to engage with new models of care, with 14% of millennials saying that they had ‘remotely interacted with a doctor via phone, chat, video chat, or another method’, compared with only 9% of the silent generation.


This is an interesting observation when compared to the growing numbers of solutions that are targeted at this generation. Within the VHA space in particular, voice assistants for senior and elderly care is one of the most densely populated categories. While these solutions have the potential to aid in tasks like medication reminders and remote monitoring, it is imperative that they are designed with the end user in mind, recognising that many people within this demographic may be lacking awareness and an understanding of these emerging models of care.


Consumer Adoption



Source: HealthXL Consumer Survey



While voice enabled health solutions have only recently made it into consumer consciousness, the survey results presented voice solutions on par in terms of consumer usage with 47% having used text based VHAs and the remaining 53% having interacted with a purely voice based or a hybrid solution.


Out of the 32% who claimed to have used a VHA, there were a number of recurring providers listed including Babylon Health, Ada Health, Google, Alexa and WebMD.


Consumers also flagged the most promising use cases for VHAs as diagnostic support (72%) followed by a relatively level playing field for management of a condition, access to education and lastly, navigating insurance plans.


The findings from our HealthXL survey correlates with those of others in the industry who have also looked at consumer adoption on digital health solutions. Rock Health, for example, showed that adoption of digital health solutions for diagnostic support has grown over time, with respondents reporting using wearables more and more to manage a disease and using them less to merely motivate a physically active lifestyle.


The use of digital health solutions for diagnostic support, particularly in the triage and symptom checker space, have benefits for key stakeholders across the entire ecosystem. For patients, the solutions provide a route by which they can save money, by reducing unnecessary face-to-face visits and increasing access to appropriate services and referrals. For providers, they enable the expansion of care services while simultaneously reducing in-person visits and healthcare practitioner burden and workload. For payers, they can leverage such solutions to scale their care management capabilities, and for pharma, they provide information to ongoing symptom management.



Consumer Trust

   

                   

Source: HealthXL Consumer Survey


With only 32% of respondents stating they have used a VHA or Chatbot, we wanted to explore how much trust consumers have in these solutions, and if a lack of trust was a factor contributing to limited adoption. The results showed that 48% of respondents said they would trust a VHA, while 46% expressed a general willingness to adopt if the right information was available.


60% of respondents noted that they would feel the need to get a second opinion from a doctor, which indicates a lack of confidence in the information received when using VHAs. These solutions must mature and gain trust in order to fulfil the promise of reducing costs and improving outcomes.


The survey results highlight that in order to have wider adoption of these solutions, it is necessary for consumers (and other stakeholders) to be supported to understand their options when it comes to VHAs, and how this usage sits with their regular interactions with the healthcare system.

Clinician Survey: What We Found

In tandem with our consumer survey, we reached out to a number of clinicians around the world to gauge their perception of the emerging VHA solutions being increasingly leveraged by their patients and targeted at their own practice.


A shared awareness of what VHA and digital health solutions are on offer to consumers, in addition to an understanding of how clinical stakeholders perceive these solutions is necessary to continue their effective scaling. This increased awareness across the board, in addition to regulatory and tech advances will ultimately lead to increased trust and adoption.


Some of the key findings from our clinical survey included:


Clinical Awareness


Source: HealthXL Consumer Survey



Awareness is the first step towards adoption of VHAs in clinical communities and beyond. Interestingly, the HealthXL Clinician survey on VHA perceptions highlighted a correlation between the most promising use cases identified by clinicians and the number of solutions on the market that are focused on addressing these use cases, namely those encouraging and supporting self management. A resounding 80% of clinicians identified ‘Encouraging Self-Management and Medication Adherence’ as the most promising use case for VHA. Of the solutions we identified in our landscape analysis, the majority of companies on the market are focused on this sub-segment of disease management including self management and medication adherence.


Remote monitoring of vitals came in second with 70% of respondents seeing VHA potential to support their patients, a capability that often goes hand in hand with encouraging certain self-management behaviours. This highlights a lacking feedback loop that traditionally exists in healthcare and a real problem that VHAs may be able to support addressing.  


In order to realise this potential continued clinical awareness of the general VHA applications available to consumers should be encouraged in order to allow clinical stakeholders to appropriately respond to, guide and support their patients to appropriately integrate reliable solutions into their health plans.



Clinical Adoption

Source: HealthXL Clinician Survey



Many VHAs have gained momentum by making their way directly into the hands of consumers through app stores and sleek websites, however, the clinical community presents a harder nut to crack as highlighted by our survey. Our own research has shown us that a larger proportion of companies in this space are leading with a patient first approach.


While 90% of clinicians surveyed claimed to not currently use any form of VHA as a part of their practice or interactions with patients, 100% of respondents said that they would feel comfortable recommending a VHA to patients in the future given some progress in the field and increased awareness of the key opportunities and limitations. This insight suggests that while clinicians recognise the potential of VHAs, they believe that the technology is not ready yet. Innovators will have some way to go before VHAs are confidently integrated into clinical practices as standard of care, but with the right level of dialogue and necessary steps towards clinical validation and RWE, it is only a matter of time before these solutions become a clinical companion.



Clinical Trust


Source: HealthXL Clinician Survey


The perception that the underlying artificial intelligence powering these VHAs is not mature enough is a key barrier to overcome before we see widespread adoption of VHAs by clinicians with 72% of clinician respondents citing this as the key barriers to their lack of adoption in their own practices. Clinicians do not want another tool that will fragment care further, so VHAs must have the capability to seamlessly integrate into existing workflows, for both the clinician and the patient, and provide insightful and actionable information.


There are also significant concerns regarding privacy and data security which are preventing clinicians from recommending VHAs to patients. With the recent announcement of Amazon’s Alexa becoming HIPAA compliant through combined efforts from healthcare providers and Amazon alike, we are making progress towards validating these solutions.

So, Where Do We Go From Here?

Many push factors are at play encouraging the scale of VHAs serving clinicians and consumers.

Impactful and long term adoption of VHAs by clinicians and consumers will be dependant on building trust in the technology’s capability and clinical validity in addition to building a shared understanding of the different VHA application types on offer.

Full report available HERE

**methodology - Consumer Survey: Leveraged Amazon Mechanical Turk to survey a random sample of 50 consumers globally, using Mechanical Turk masters criteria, in February 2019. Clinician Survey: We reached out to 11 clinicians globally to gauge their perception of the space.


Upcoming HealthXL Q2 Report - Digital Health Evidence Review 2019

Our Q2 Report is brewing - Digital Health Evidence Review 2019. The report aims to identify, categorize, and summarise all existing, relevant studies in digital health. Through this report, we want to establish a clear understanding of the existing body of clinical evidence for digital health, its maturity, current gaps and needs. Do you have specific questions on clinical validation for DH? Reach out to us - we'd love to get your ideas and answer your pain points.


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.